Published in Cancer Epidemiol Biomarkers Prev on January 12, 2012
Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 1.29
Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol (2013) 1.20
Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis. Br J Cancer (2014) 0.92
Precision prevention of oesophageal adenocarcinoma. Nat Rev Gastroenterol Hepatol (2015) 0.88
Obesity and inflammation markers in relation to leukocyte telomere length in a cross-sectional study of persons with Barrett's esophagus. BMC Obes (2015) 0.84
Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition. World J Gastrointest Pharmacol Ther (2013) 0.84
NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. BMJ Open (2015) 0.80
Medical Prevention of Barrett's Esophagus: Effects of Statins, Aspirin, Non-aspirin NSAIDs, Calcium, and Multivitamins. Dig Dis Sci (2015) 0.79
Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort. Gastrointest Endosc (2016) 0.77
Statin use and risk of prostate cancer: Results from the Southern Community Cohort Study. Prostate (2015) 0.76
Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. Gut (2016) 0.75
Ischemic heart disease, factor predisposing to Barrett's adenocarcinoma: A case control study. World J Gastrointest Pharmacol Ther (2014) 0.75
Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview. Ann Gastroenterol (2016) 0.75
Use of Cyclo-Oxygenase Inhibitors Is Not Associated with Clinical Relapse in Inflammatory Bowel Disease: A Case-Control Study. Pharmaceuticals (Basel) (2015) 0.75
Risk stratification for malignant progression in Barrett's esophagus: Gender, age, duration and year of surveillance. World J Gastroenterol (2016) 0.75
Statins and the risk of colorectal cancer. N Engl J Med (2005) 6.86
Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ (2010) 5.19
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med (2000) 3.31
Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf (2008) 2.43
Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol (2005) 2.40
Statin use and cancer risk in the General Practice Research Database. Br J Cancer (2004) 2.34
Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer (2009) 2.33
Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst (2011) 2.27
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med (2007) 2.23
Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest (2001) 2.19
Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation (2002) 2.17
Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest (2007) 2.15
Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol (2008) 2.03
Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol (2009) 1.83
Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res (2011) 1.76
Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology (2010) 1.51
Statins in tumor suppression. Cancer Lett (2008) 1.34
Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol (2009) 1.29
Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology (2011) 1.25
Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. Anticancer Res (2000) 1.11
Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology (2003) 1.09
Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas (2007) 1.09
Cancer as an evolutionary and ecological process. Nat Rev Cancer (2006) 9.33
Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet (2006) 6.71
Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology (2003) 3.58
Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer (2010) 3.27
Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol (2007) 3.18
Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst (2003) 3.07
Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol (2007) 3.00
Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol (2005) 2.40
Leukocyte telomere length predicts cancer risk in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev (2007) 2.39
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med (2007) 2.23
Central adiposity and risk of Barrett's esophagus. Gastroenterology (2007) 2.20
Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res (2004) 2.15
Carbonated soft drink consumption and risk of esophageal adenocarcinoma. J Natl Cancer Inst (2006) 2.08
Racial disparities among patients with lung cancer who were recommended operative therapy. Arch Surg (2009) 2.02
A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology (2006) 1.98
A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila) (2010) 1.89
Thyrotropin levels in a population with no clinical, autoantibody, or ultrasonographic evidence of thyroid disease: implications for the diagnosis of subclinical hypothyroidism. J Clin Endocrinol Metab (2008) 1.77
The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res (2004) 1.76
Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg (2010) 1.68
A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet (2013) 1.67
Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst (2010) 1.60
Focus on Barrett's esophagus and esophageal adenocarcinoma. Cancer Cell (2004) 1.57
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
Occupational exposures and risks of liver cancer among Shanghai female textile workers--a case-cohort study. Int J Epidemiol (2005) 1.50
Reproducible two-dimensional capillary electrophoresis analysis of Barrett's esophagus tissues. Anal Chem (2006) 1.49
Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology (2011) 1.44
Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression. Cancer Prev Res (Phila) (2008) 1.43
Single nucleotide polymorphism array analysis of flow-sorted epithelial cells from frozen versus fixed tissues for whole genome analysis of allelic loss in breast cancer. Am J Pathol (2002) 1.39
Extended lifespan of Barrett's esophagus epithelium transduced with the human telomerase catalytic subunit: a useful in vitro model. Carcinogenesis (2003) 1.39
Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium. Eur J Cancer Prev (2016) 1.38
Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin N Am (2003) 1.36
Chlamydia pneumoniae and lung cancer: epidemiologic evidence. Cancer Epidemiol Biomarkers Prev (2005) 1.31
Sinonasal cancer and occupational exposures: a pooled analysis of 12 case-control studies. Cancer Causes Control (2002) 1.31
Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus. Cancer Prev Res (Phila) (2013) 1.31
Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol (2012) 1.30
Prior lung disease and risk of lung cancer in a large prospective study. Cancer Causes Control (2004) 1.30
Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol (2013) 1.29
Cigarette smoking increases risk of Barrett's esophagus: an analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Gastroenterology (2012) 1.28
Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol (2013) 1.28
Thyroid neoplasia, autoimmune thyroiditis, and hypothyroidism in persons exposed to iodine 131 from the hanford nuclear site. JAMA (2004) 1.26
Childhood thyroid cancer, radiation dose from Chernobyl, and dose uncertainties in Bryansk Oblast, Russia: a population-based case-control study. Radiat Res (2006) 1.26
Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH. Genes Chromosomes Cancer (2007) 1.26
Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett's esophagus, and gastroesophageal reflux. J Natl Cancer Inst (2013) 1.25
Spectrum and risk of neoplasia in Werner syndrome: a systematic review. PLoS One (2013) 1.23
Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus. Am J Surg Pathol (2009) 1.22
Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity. Cancer Epidemiol Biomarkers Prev (2004) 1.22
Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers. Clin Gastroenterol Hepatol (2005) 1.21
A clinical risk prediction model for Barrett esophagus. Cancer Prev Res (Phila) (2012) 1.21
Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut (2011) 1.18
Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction. Obesity (Silver Spring) (2010) 1.18
Chlamydia pneumoniae infection and risk of lung cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.18
Genetic variation in the prostate stem cell antigen gene and upper gastrointestinal cancer in white individuals. Gastroenterology (2010) 1.18
Food group intake and risk of subtypes of esophageal and gastric cancer. Int J Cancer (2008) 1.17
Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res (2009) 1.17
Genetic variation in C20orf54, PLCE1 and MUC1 and the risk of upper gastrointestinal cancers in Caucasian populations. Eur J Cancer Prev (2012) 1.17
Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev (2002) 1.14
Neosquamous epithelium does not typically arise from Barrett's epithelium. Clin Cancer Res (2006) 1.14
Risk factors for Barrett's esophagus among patients with gastroesophageal reflux disease: a community clinic-based case-control study. Am J Gastroenterol (2009) 1.14
Trends in the incidence rates of nasopharyngeal carcinoma among Chinese Americans living in Los Angeles County and the San Francisco metropolitan area, 1992-2002. Am J Epidemiol (2005) 1.13
Chromosomal instability in Barrett's esophagus is related to telomere shortening. Cancer Epidemiol Biomarkers Prev (2006) 1.12
Natural selection in neoplastic progression of Barrett's esophagus. Semin Cancer Biol (2005) 1.10
Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus. Hum Pathol (2006) 1.08
The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus. PLoS One (2013) 1.08
CD14-159C/T and TLR9-1237T/C polymorphisms are not associated with gastric cancer risk in Caucasian populations. Eur J Cancer Prev (2009) 1.07
Direct inference of SNP heterozygosity rates and resolution of LOH detection. PLoS Comput Biol (2007) 1.06
Transcriptional analyses of Barrett's metaplasia and normal upper GI mucosae. Neoplasia (2002) 1.03
Molecular phenotype of spontaneously arising 4N (G2-tetraploid) intermediates of neoplastic progression in Barrett's esophagus. Cancer Res (2003) 1.02